Home / Business and Economy / UK Drug Deal Secures Faster Access to Life-Saving Treatments
UK Drug Deal Secures Faster Access to Life-Saving Treatments
6 Jul
Summary
- New medicines for cancer and autoimmune diseases reach patients faster.
- NHS now offers 48 out of 100 newly launched medicines within the first year.
- Pricing reform has updated NICE cost-effectiveness thresholds after 25 years.
The UK's reformed pharmaceutical pricing arrangements are ensuring that many new medicines are now reaching NHS patients. This significant progress follows an update to the National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold, which had not been adjusted in almost a quarter of a century.
Previously, the NHS lagged behind comparable European countries in providing access to innovative treatments, especially for cancer and rare diseases. The updated threshold aims to rectify this, enabling faster access to crucial therapies for patients suffering from various cancers, blood disorders, and autoimmune conditions.
Government figures reveal that for every 100 patients receiving a newly launched medicine in comparable countries during its first year, only 48 do so in the UK. The recent pharmaceutical agreement seeks to eliminate this inequity, bringing British patient care closer to international standards.
